XTX Topco Ltd Takes Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

XTX Topco Ltd purchased a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 49,878 shares of the company’s stock, valued at approximately $144,000. XTX Topco Ltd owned 0.09% of Fulcrum Therapeutics as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. MetLife Investment Management LLC boosted its holdings in Fulcrum Therapeutics by 145.8% during the fourth quarter. MetLife Investment Management LLC now owns 40,107 shares of the company’s stock worth $189,000 after purchasing an additional 23,792 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Fulcrum Therapeutics during the fourth quarter worth $38,000. Millennium Management LLC boosted its holdings in Fulcrum Therapeutics by 224.0% during the fourth quarter. Millennium Management LLC now owns 76,123 shares of the company’s stock worth $358,000 after purchasing an additional 52,628 shares during the last quarter. Northern Trust Corp boosted its holdings in Fulcrum Therapeutics by 25.1% during the fourth quarter. Northern Trust Corp now owns 710,321 shares of the company’s stock worth $3,339,000 after purchasing an additional 142,578 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Fulcrum Therapeutics by 34.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company’s stock worth $161,000 after purchasing an additional 8,761 shares during the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Wall Street Analyst Weigh In

FULC has been the subject of several recent research reports. Wall Street Zen cut shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 target price for the company in a report on Thursday, May 15th. Leerink Partners raised shares of Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $4.00 to $12.00 in a research report on Friday, May 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $9.00 price target (up from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. Finally, Leerink Partnrs raised shares of Fulcrum Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 23rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Fulcrum Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $7.57.

Fulcrum Therapeutics Trading Up 4.7%

NASDAQ FULC opened at $6.85 on Thursday. The firm has a market capitalization of $370.52 million, a P/E ratio of -5.61 and a beta of 2.47. The firm’s fifty day moving average price is $7.15 and its two-hundred day moving average price is $5.14. Fulcrum Therapeutics, Inc. has a 1 year low of $2.32 and a 1 year high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01. On average, research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.